[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-359135-105":59,"doc-detail-359135-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","construction-and-application-of-a-genetically-engineered-mouse-model-of-gastric-adenocarcinoma","Construction and application of a genetically engineered mouse model of gastric adenocarcinoma","","Background: The lack of specific and immunocompetent gastric cancer models has limited research on gastric adenocarcinoma (GAC). Methods: A tamoxifen-inducible CRISPR-based Anxa10-CreERT2 mouse was crossed with KrasG12D/+ and Tp53R172H/+ strains to generate a C57BL/6J model. Tamoxifen and N-methyl-N-nitrosourea induced in situ tumors, confirmed by histology and PET/CT, then an allograft (MDA) and stable GAC cell line (ST-YC19) were established. Results showed high-incidence intestinal-type CIN-like tumors with aggressive ST-YC19 traits and limited anti-PD-1 sensitivity. Conclusion: The model supports in vivo investigation of progression, metastasis, therapeutic response, and resistance, aiding precision medicine.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/construction-and-application-of-a-genetically-engineered-mouse-model-of-gastric-adenocarcinoma/359135/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/construction-and-application-of-a-genetically-engineered-mouse-model-of-gastric-adenocarcinoma/359135.png","ImageObject",300,407,{"name":92,"@type":93},"Ophelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":81},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is a genetically engineered, immunocompetent gastric cancer model needed?","Question",{"text":112,"@type":113},"Because earlier research has been hindered by the lack of specific and immunocompetent gastric cancer models, which limits study of gastric adenocarcinoma biology and treatment responses.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the mouse GAC model constructed and induced?",{"text":117,"@type":113},"A tamoxifen-inducible CRISPR-based Anxa10-CreERT2 line was crossed with KrasG12D/+ and Tp53R172H/+ strains on a C57BL/6J background, then tamoxifen and N-methyl-N-nitrosourea were used to induce in situ tumor development.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the key findings about tumor characteristics and immunotherapy response?",{"text":121,"@type":113},"Spontaneous GAC showed 100% incidence within 2.5 months, mainly intestinal type, and essential CIN subtype molecular features. The derived ST-YC19 cells were aggressive with metastasis and showed limited sensitivity to anti-programmed death-1 immunotherapy.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},359135,1791121400,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":81,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41},7971461741311,"https://ap-avatar.wpscdn.com/avatar/74000253aff267980c6?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779345379180704826","J Chin MedAssoc  \nOriginal article  \nConstruction and application of a genetically engineered mouse model of gastric adenocarcinoma  \nYelizhati Madetia, Xiaoyi Chonga, Xiaotian Zhangb,c,*  \naKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, China; bState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, China; cDepartment of Medical Oncology, Affiliated Cancer Hospital of Inner Mongolia Medical University (Peking University Cancer Hospital Inner Mongolia Hospital), Hohhot, China  \nAbstract  \nBackground: The lack of specific and immunocompetent gastric cancer models has hindered the exploration of gastric adenocarcinoma (GAC) . We constructed a spontaneous and transplantable GAC model using a genetically engineered mouse.  \nMethods: We generated a tamoxifen-inducible CRISPR-based Anxa10-CreERT2 mouse line and crossed it with the KrasG12D/+ andTp53R172H/+ strains to develop Anxa10-CreERT2; KrasG12D/+; Tp53R172H/+ mice on a C57BL/6J background. Tamoxifen and N-methyl-N-nitrosourea were administered to induce in situ tumor development. An orthotopic gastric tumor was confirmed by histological analysis and positron emission tomography/computed tomography. A transplantable mouse-derived allograft (MDA) model and stable GAC cell line (ST-YC19) were subsequently established using MDA. The malignant characteristics and drug responses were evaluated.  \nResults: Spontaneous GAC had a 100% incidence within 2.5 months, was predominantly of the intestinal type, and presented essential molecular features of the CIN subtype. The ST-YC19 GAC cell line derived from MDAs exhibited an aggressive phenotype, robust tumorigenic potential, peritoneal dissemination, and distant metastasis. This model showed limited sensitivity to antiprogrammed death-1 immunotherapy.  \nConclusion: We successfully established a spontaneous GAC model and its corresponding cell line in C57BL/6J mice, enabling a comprehensive investigation of tumor progression, metastasis, therapeutic response, and resistance mechanisms in vivo. This model represents a valuable platform for advancing precision medicine in gastric cancer.  \nKeywords: Adenocarcinoma; Gastric cancer; Genetically engineered mouse model; Immunocompetent mice  \n[www.ejcma.org](www.ejcma.org) 243  \nMadeti et al. J Chin MedAssoc  \nLay Summary: Stomach cancer research has been hindered by the lack of realistic animal models that mimic the growth and response of human tumors to treatments. To address this, we created a new mouse model using genetic engineering to develop stomach cancer spontaneously, similar to that in humans. By activating specific cancer-causing gene changes in mice, tumors formed reliably within 2.5 months. These tumors can be transplanted into healthy mice or grown as cell lines in the laboratory, thereby allowing us to study how cancer spreads and test therapies. The model demonstrated resistance to a widely used immunotherapy (anti-programmed death-1), highlighting its usefulness in exploring why some treatments fail. This breakthrough provides a powerful tool for studying stomach cancer progression, testing new drugs, and personalizing treatments for patients, bringing us closer to achieving better outcomes for this deadly disease.  \n1. INTRODUCTION  \nGastric cancer (GC) is among the most prevalent malignant tumors worldwide, ranking fifth in incidence and mortality as of 2022.1 Immunotherapies, including anti-programmed death-1 (PD1),2,3 and targeted treatments such as anti-HER2/ Claudin18.2,4,5 have been applied to GC. However, the limited response of many patients underscores the heterogeneity of GC and the need for a deeper understandi","cbCaisOBPPYGrv8f","https://ap.wps.com/l/cbCaisOBPPYGrv8f","pdf",11828155,12,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Introduction\n## Gastric cancer burden and therapies\n## Animal model needs\n## Existing in vivo model approaches\n## Limitations of current models","[{\"question\":\"Why is a genetically engineered, immunocompetent gastric cancer model needed?\",\"answer\":\"Because earlier research has been hindered by the lack of specific and immunocompetent gastric cancer models, which limits study of gastric adenocarcinoma biology and treatment responses.\"},{\"question\":\"How was the mouse GAC model constructed and induced?\",\"answer\":\"A tamoxifen-inducible CRISPR-based Anxa10-CreERT2 line was crossed with KrasG12D/+ and Tp53R172H/+ strains on a C57BL/6J background, then tamoxifen and N-methyl-N-nitrosourea were used to induce in situ tumor development.\"},{\"question\":\"What were the key findings about tumor characteristics and immunotherapy response?\",\"answer\":\"Spontaneous GAC showed 100% incidence within 2.5 months, mainly intestinal type, and essential CIN subtype molecular features. The derived ST-YC19 cells were aggressive with metastasis and showed limited sensitivity to anti-programmed death-1 immunotherapy.\"}]","Construction and application of a genetically engineered mouse model of gastric adenocarcinoma | PDF",1790136195]